Risk difference of liver-related and cardiovascular events by liver fibrosis status in nonalcoholic fatty liver disease

2021 ◽  
Author(s):  
Nobuharu Tamaki ◽  
Mayu Higuchi ◽  
Masayuki Kurosaki ◽  
Rohit Loomba ◽  
Namiki Izumi ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Cardiovascular Events ◽  
Risk Difference ◽  
Nonalcoholic Fatty Liver

427-P: Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Are Mutually Independent Predictors of Cardiovascular Events in Patients with Established Cardiovascular Disease

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 427-P
Author(s):  
CHRISTOPH H. SAELY ◽  
ALEXANDER VONBANK ◽  
MAXIMILIAN MAECHLER ◽  
BARBARA LARCHER ◽  
LUKAS SPRENGER ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Cardiovascular Events ◽  
Nonalcoholic Fatty Liver ◽  
Mutually Independent

scholarly journals Prevalence of clinically relevant liver fibrosis due to nonalcoholic fatty liver disease in Indian individuals with type 2 diabetes

JGH Open ◽  
2021 ◽  
Author(s):  
Mohammad Shafi Kuchay ◽  
Narendra Singh Choudhary ◽  
Sunil Kumar Mishra ◽  
Tarannum Bano ◽  
Sakshi Gagneja ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

M1988 Noninvasive Markers of Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease (NAFLD)

2010 ◽  
Vol 138 (5) ◽  
pp. S-453 ◽  
Author(s):  
Naim Alkhouri ◽  
Christine A. Carter-Kent ◽  
Anna Alisi ◽  
Ariel E. Feldstein ◽  
Valerio Nobili
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Noninvasive Markers

scholarly journals Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease

Hepatology ◽  
2010 ◽  
Vol 51 (4) ◽  
pp. 1209-1217 ◽  
Author(s):  
Luca Valenti ◽  
Ahmad Al-Serri ◽  
Ann K. Daly ◽  
Enrico Galmozzi ◽  
Raffaela Rametta ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver

scholarly journals Noninvasive diagnosis of liver fibrosis in patients with nonalcoholic fatty liver disease

2017 ◽  
Vol 51 (3) ◽  
pp. 188-195 ◽  
Author(s):  
Yu.M. Stepanov ◽  
N.V. Nedzvetskaya ◽  
V.B. Yagmur ◽  
I.A. Klenina ◽  
N.Yu. Oshmyanskaya
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Noninvasive Diagnosis ◽  
Nonalcoholic Fatty Liver

Abstract 14339: Nonalcoholic Fatty Liver Disease and the Risk of Clinical Cardiovascular Events: A Meta-Analysis

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Toufik Mahfood Haddad ◽  
Shadi Hamdeh ◽  
Mahesh Anantha Narayanan ◽  
Arun Kanmanthareddy ◽  
Venkata M Alla
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Publication Bias ◽  
Fatty Liver Disease ◽  
Cardiovascular Events ◽  
Meta Analysis ◽  
Significant Heterogeneity ◽  
Cross Sectional ◽  
Nonalcoholic Fatty Liver

Background: Numerous studies have assessed the association of Nonalcoholic fatty liver disease (NAFLD) withcardiovascular disease (CVD). However, results have been conflicting due to variability in definitionsof NAFLD and ascertainment of CVD, often combining clinical and surrogate endpoints. We therefore systematically reviewed published literature to assess the association between NAFLD and clinical cardiovascular events. Methods: We searched Medline, Cochrane, google scholar, CINAHL, and Web of Sciencedatabasesusing terms “nonalcoholic fatty liver disease”, “cardiovascular disease”, and their combinations to identify studies published through March 2015. Data from selected studies was extracted and meta-analysis was then performed using Random effects model following the PRISMA guidelines. Publication bias and heterogeneity wereassessed. The main outcome measure was Odds ratio (OR) with 95% CI. Clinical CVD was defined as symptomatic coronary artery disease, myocardial infarction, coronary or peripheral intervention, ischemic stroke, and symptomatic peripheral vascular disease. Results: A total of 7 studies with 14634 patients (NAFLD: 4204; controls: 10430) were included in the final analysis. 3 studies were cross- sectional reporting prevalence, while 4 studies were prospective cohort studies reporting incidence. Patients with NAFLD had a significantly higher risk of clinical CVD compared to controls [OR: 3.17; 95% CI: 1.89-5.30, P<0.01) (figure 1A). There was significant heterogeneity (I2=93%). Funnel plot and Begg’s test did not reveal significant publication bias. Separate analyses of the cohort and cross sectional studies and exclusion sensitivity analysis did not alter the findings (figure 1B). Conclusion: NAFLD is associated with a three fold increase in the risk of clinical CVD compared to controls without NAFLD. These results need to be conformed in large prospective studies.

Sign in / Sign up

Export Citation Format

Share Document